Experienced in Hypophosphatemia

Feng Bi

Chengdu, CN 
Experienced in Hypophosphatemia
Chengdu, CN 
OverviewLocationsClinical Research

Overview

Feng Bi practices in Chengdu, China. Mr. Bi is rated as an Experienced expert by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Colorectal Cancer, Stomach Cancer, Lung Metastases, Liver Cancer, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 176 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypophosphatemia.

Gender
Male

Locations

Chengdu, China
Other Locations
Changsha, 410013, China
China
P.R. China, Yancheng, China
Beijing, 100142, China
Nanjing, China
Huaxi, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Biological
Study Drug: JS001 Anti-PD-1 Antibody
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

176 Total Publications

Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.
Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bi's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile